Actively Recruiting
Evaluating Once-Monthly Berobenatide Injections for Adults With Obstructive Sleep Apnea and Overweight or Obesity Using Positive Airway Pressure Therapy
Led by Pfizer · Updated on 2026-10-13
258
Participants Needed
6
Research Sites
7 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of a study medicine called berobenatide in adults who have breathing problems during sleep known as obstructive sleep apnea OSA and who are overweight or obese. The study focuses on people who use a positive airway pressure PAP machine to help with their breathing during sleep. Participants will be adults with moderate to severe OSA who have been using PAP therapy before joining. Participants will be randomly assigned to receive either berobenatide or a placebo. The study treatment is given as an injection under the skin about once a month. Some doses will be administered at study sites, while others may be given at home after training. This is a phase 3 study with a double-blind design, so neither the participants nor the researchers know who receives the study medicine or placebo. During the study, participants will attend visits, undergo sleep studies, complete questionnaires, and have health assessments. Researchers will measure changes in breathing during sleep using the Apnea-Hypopnea Index AHI and also track body weight and other health indicators. The study will monitor safety and effectiveness over about one year, with the main outcome measured at 52 weeks.
CONDITIONS
Brief Title
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here